ABVC BIOPHARMA, INC. (ABVC): Nasdaq/NYSE listing notice — ABVC BioPharma fails to regain Nasdaq bid-price compliance by Feb 14; granted extension to Aug 14, 2023

ABVC BIOPHARMA, INC.

Company missed initial Feb 14, 2023 deadline to close at $1.00 for 10 consecutive business days.
Nasdaq granted an additional 180-day compliance period, now expiring August 14, 2023.
If bid price closes at $1.00 or more for 10 consecutive days before Aug 14, compliance confirmed.
Failure to regain compliance by Aug 14 could lead to delisting; Company may appeal.
Common stock continues trading on Nasdaq Capital Market under symbol ABVC in the interim.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ABVC BIOPHARMA, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

August 19, 2022, ABVC BioPharma, Inc. (the “ Company ”) filed a Current Report on Form 8-K to report that it received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“ Rule 5550(a)(2) ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Compan

View on SEC.gov

Browse all listing & compliance notices →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-012464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.